anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This proposed study will be an ancillary study to clinical trial NCT00555997 (www.clinicaltrials.gov) entitled: "A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Sequential Trial of Ziprasidone as Monotherapy for Major Depressive Disorder" (MDD)." Precision Human Biolaboratory ("PHB") is attempting to develop a proprietary blood test intended to potentially serve as a biological marker ("bio-marker") for MDD. Specifically, PHB's research team will employ a unique approach towards developing a diagnostic test for MDD: measures from multiple blood-based biological markers will be obtained from patients with MDD and then analyzed with the use of several interrelated algorithms in order to derive a single biological measure ("bio-marker") with a high predictive value for MDD. PHBs' test panel of blood-based biological markers will consist of a number of cytokines, stress related hormones, and binding proteins that have each been linked to MDD. This innovative test panel is expected to provide general practice physicians with a tool to more accurately identify and classify patients with MDD which, in turn, could potentially , allow for the more effective monitoring of pharmacotherapy (antidepressant drug therapy). Thus, the development of a highly reliable biomarker for MDD could improve the standard of care for depression.

For this ancillary study, 120 antidepressant-free outpatients with MDD who have been deemed eligible to participate in trial NCT00555997 will be recruited from participating centers. Participating subjects will undergo a blood draw during the baseline visit for NCT00555997. Values obtained will be compared with those of "healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.
<P>PROBLEM TO BE SOLVED: To obtain a foamable aerosol composition which does not require shaking of a container before discharge, is dischargeable in a placed state on a basin and forms stable foams regardless of temperature change.  <P>SOLUTION: The aerosol composition comprises a fatty acid, an alkali agent, liquefied gas and compressed gas. When the aerosol composition is discharged, a part or the whole of the fatty acid is made into a fatty acid salt with the alkali agent. The aerosol composition contains a higher alcohol. The content of the liquefied gas is preferably 0.1-10 wt.% in the aerosol composition. The compressed gas is preferably carbon dioxide gas and/or nitrous oxide.  <P>COPYRIGHT: (C)2003,JPO
There is a bidirectional relationship between Obstructive Sleep Apnea (OSA) and obesity. Although obesity can lead to OSA, patients with OSA are more likely to gain weight. The mechanisms that lead to weight gain during the treatment of OSA are not known. Some evidence supports the hypothesis that fluid accumulation could be a possible explanation for weight gain after treatment for OSA. The hypothesis is that one night of CPAP treatment promotes increased body weight and reduced diuresis in patients with OSA. Participants will be submitted to 2 consecutive nights of polysomnography (PSG). A baseline PSG will be performed during the first study visit. During the second study night, participants will be randomized into two groups, CPAP and control (repeat baseline PSG). Overnight urinary volume will be determined. Intra and extracellular water volume will be assessed using electrical bioimpedance before bedtime and just after the subject wakes up. Plasmatic BNP and ADH and urinary osmolality will also be determined during each morning following PSG.
Extended phenytoin sodium capsules, USP are available as 200 mg or 300 mg of phenytoin sodium, USP 

  * The 200 mg capsule has a blue transparent cap and a light blue transparent body. The hard-shell gelatin capsule is filled with white to off-white powder. The capsule is printed axially with 299 in black ink on both the cap and the body.
  * The 300 mg capsule has a light blue transparent cap and a light blue transparent body. The hard-shell gelatin capsule is filled with white to off-white powder. The capsule is printed axially with 432 in black ink on both the cap and the body.
Part 2: acapatamab is administered intravenously at the MTD/RP2D. Pembrolizumab will be administered intravenously.
<P>PROBLEM TO BE SOLVED: To obtain a film-coated tablet having a hardly breakable coated layer even in coating an uncoated tablet having a high coefficient of cubic expansion with a small amount of film, a film-coated tablet having a masked smell and to provide a method for masking a smell of an uncoated tablet having a strong smell.  <P>SOLUTION: The film-coated tablet comprises an uncoated tablet and a coated film layer for coating the uncoated tablet. The uncoated tablet exhibits 5-50% coefficient of cubic expansion when allowed to stand in an uncoated state at 25°C in an atmosphere at 60% humidity for 24 hours. The film-coated layer comprises polyvinyl alcohol. The film-coated tablet having a reduced smell of an uncoated tablet comprises an uncoated tablet and a coated layer for coating the uncoated tablet. The film-coated layer comprises polyvinyl alcohol. The amount of the film-coated layer formed is ≤10 mass% based on the uncoated tablet. The method for masking a smell is provided.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PCT No. PCT/EP89/00376 Sec. 371 Date Oct. 9, 1990 Sec. 102(e) Date Oct. 9, 1990 PCT Filed Apr. 6, 1989 PCT Pub. No. WO89/09625 PCT Pub. Date Oct. 19, 1989.There is provided a method of generating enhanced images of the human or non-human animal body, for example for use in medical diagnosis, which involves administering to the body a positive MRI contrast agent which is body tissue- or body duct-specific following the particular mode of administration and a negative MRI contrast agent which preferably also is body tissue- or body duct-specific. Thereafter a magnetic resonance image is generated of a part of the body containing the negative and positive contrast agents or their paramagnetic, ferromagnetic or superparamagnetic biodegradation products. Contrast media suitable for use in this new image generating method are also provided.
A composition for controlling bacterial growth/colonization is provided. The composition comprises an enzyme, an anchor molecule coupled to the enzyme to form an enzyme-anchor complex, with the anchor being capable of attaching to a substrate proximal to a bacterial colony. The composition is produced using recombinant DNA techniques. In one form, the composition is a fusion protein coded for by a polynucleotide segment. The attachment to the substrate permits prolonged retention time of the enzyme-anchor complex where the bacterial colony is present to increase the effectiveness of the complex. The invention is also for a method of controlling colonization of bacterial plaque in the oral cavity, as well as a method of forming a composition for controlling the proliferation of bacterial colonies in the oral cavity.
PROBLEM TO BE SOLVED: To provide an antimicrobial medical composition that contains an ethyenylidene bisphosphonic acid as an active ingredient and is useful for treatment of infections by pathogenic microorganisms. SOLUTION: This antimicrobial composition contains 0.1-95 wt.% of a compound of the formula (R<1> -R<4> are each 1-7C alkyl), typically tetraalkyl ethenylidene bis(phosphonate). In addition, usual pharmaceutical carrier is properly formulated to form soap, cream, capsule, solution, mouth-washing, tooth paste, shampoo and the like. The compound of the formula is useful for excluding Streptococcus mutans, causing tooth decay; Welch bacillus causing gas gangrene, Escherichia coil or other inner-intestinal bacteria causing urinary tract infection and gastrointestinal disease, Staphylococcus aureus causing gastrointestinal diseases and skin infections, Staphylococcus aureus causing vaginal infection and Escherichia coil, Staphylococcus aureus. Proteus vulgaris causing urinary tract infection. The daily dose is 1-10,000 mg/kg, preferably 1-250 mg/kg.
During a single session intervention, participants will perform 2 sets of 2 minutes of pelvic tilt exercises without a serious game. Patients will perform the exercises in a standing position. The number of repetitions and the tempo of the pelvic tilts will be indicated using a metronome.
Study visits monthly (Week 0, 4, and 8), with phone visits every other week (Week 2 and 6). Double-blind, placebo-controlled treatment with escitalopram 10mg/day, raised to 20mg/day, if non-responders at week 4.
Patients above the age of 60 years will be enrolled in a separate, exploratory cohort and receive PET-guided treatment with tislelizumab or T-AVD as described above. However, all patients in the exploratory cohort for older patients will receive consolidating 30 Gy IS-RT.
The invention discloses a traditional Chinese medicine composite for treating uterine bleeding and a preparation method thereof, belonging to the technical field of the traditional Chinese medicine. The traditional Chinese medicine composite mainly comprises the following ingredients according to the parts by weight: 6 parts of ginseng, 30 parts of raidx astragali, 10 parts of amur corktree bark,10 parts of tortoise plastron, 10 parts of baical skullcap root, 15 parts of cherokee rose fruit, 15 parts of white paeony root, 15 parts of radix polygoni multiflori preparata, 6 parts of radix glycyrrhizae preparata, 15 parts of angelica, 10 parts of nutgrass galingale rhizome, 8 parts of dried ginger, 10 parts of radix rehmanniae preparata, 15 parts of folium artemisiae argyi preparata, 15 parts of large head atractylodes rhizome and 15 parts of cyrtomium rhizome. The traditional Chinese medicine composite can also add and reduce dosages on the basis of the above prescription. The traditional Chinese medicine composite can be decocted with water and then is taken, and also can be made into mixture for taking. The traditional Chinese medicine composite has low price, simple operation, convenient to use and no toxic side effect. The patient can make by themselves and the invention has curative rate of 94.1 percent on uterine bleeding caused by various reasons and total effective rateof 100 percent, and has no relapse. Compared with other medicines, the traditional Chinese medicine composite has extremely obvious effect.
Intermittent hypoxia (IH) is a hallmark of obstructive sleep apnea (OSA), which is related to tumorigenesis and progression. We explored the possible mechanisms by which OSA may promote the development of non-small cell lung cancer (NSCLC). In this study, NSCLC cells with and without miR-106a-5p inhibition were exposed to IH or room air (RA), and subsequently, exosomes were extracted and identified. Macrophages were incubated with these exosomes to detect the expression of the STAT3 signaling pathway and M2-type macrophage markers, as well as the effect of the macrophages on the malignancy of NSCLC cells. A nude mouse tumorigenesis model was constructed to detect the effects of exosomal miR-106a-5p on M2 macrophage polarization and NSCLC cell malignancy. Our results showed that IH exosomes promoted the polarization of M2 macrophages, thereby promoting the proliferation, invasion, and metastasis of NSCLC cells. Further, Based on microarray analysis of RA and IH exosomes, we discovered that miR-106a-5p, transferred to the macrophages through exosomes, participated in this mechanism by promoting M2 macrophage polarization via down-regulating PTEN and activating the STAT3 signaling pathway in vitro and in vivo. For patients with NSCLC and OSA, exosomal miR-106a-5p levels showed a positive relation to AHI. Exosomal miR-106a-5p represents a potential therapeutic target among patients with concomitant cancer and NSCLC.
BACKGROUND: Human Papillomavirus (HPV) is a prevalent STI (Sexually Transmitted Infection) that is estimated almost all sexually active Patients at some stage of their life will be infected by the virus. Although most HPV infections resolve spontaneously, some can result in health complications, such as genital warts and several types of cancer. This study analyzed the variety of HPV genotypes in females and males among the infected population.
METHODS: Samples were obtained from the oral, vaginal, and genital sites of study participants and the samples underwent DNA extraction and subsequently amplified using Real-Time PCR. The recognition of high-risk (HR) and low-risk (LR) HPV genotypes was carried out using the HPV REALQUALITY RQ-Multi diagnostic kit and demographic information was analyzed alongside statistical virological data.
RESULTS: Out of 936 samples, 324 cases (34.6%) were found to be positive for HPV, while 612 cases (65.4%) were negative. Of our participants, 70 samples of males (27.5%) and 254 samples of females (37.3%) were HPV-positive. Common genotypes included 16, 6, 11, and 18, while genotypes 59, 56, 31, 45, and 52 were also detected.
CONCLUSION: According to the findings of this study, a significant prevalence of HPV infection was seen in males and females, and the incidence of high-risk genotypes was more diverse in males. While the vaccine was effective in preventing some types of HPV, such as 16, 18, 6, and 11, there seems to be an increase in infections caused by other genotypes, and precautions should be taken to prevent future health problems.
An antibacterial oil-in-water emulsion for inhibiting the growth of Helicobacter pylori is disclosed. The oil-in-water emulsion of the invention comprises droplets of an oily discontinuous phase dispersed in a continuous phase. The oily discontinuous phase contains an oil carrier and a glycerol ester selected from the group consisting of glycerol monooleate and glycerol monostearate. The emulsion can be positively charged, negatively charged or chargeless. In one embodiment, the emulsion is positively charged and further comprises a cationic halogen-containing compound having a C12-C16 chain as a positive charge producing agent. In another embodiment, the emulsion is negatively charged and further comprises an negative charge producing agent having a C12-C22 chain. The disclosed emulsions can be administered to individuals, for example, orally, to treat or prevent Helicobacter pylori infections.
Osteoarthritis (OA) is a common disease in middle-aged and elderly people. An imbalance in calcium ion homeostasis will contribute to chondrocyte apoptosis and ultimately lead to the progression of OA. Transient receptor potential channel 4 (TRPV4) is involved in the regulation of intracellular calcium homeostasis. TRPV4 is expressed in primary cilia, which can sense mechanical stimuli from outside the cell, and its abnormal expression is closely related to the development of OA. Low-intensity pulsed ultrasound (LIPUS) can alleviate chondrocyte apoptosis while the exact mechanism is unclear. In this project, with the aim of revealing the mechanism of action of LIPUS, we proposed to use OA chondrocytes and animal models, LIPUS intervention, inhibition of primary cilia, use TRPV4 inhibitors or TRPV4 agonist, and use Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB), Quantitative Real-time PCR (QP) to detect the expression of cartilage synthetic matrix and endoplasmic reticulum stress markers. The results revealed that LIPUS altered primary cilia expression, promoted synthetic matrix metabolism in articular chondrocytes and was associated with primary cilia. In addition, LIPUS exerted a active effect on OA by activating TRPV4, inducing calcium inward flow, and facilitating the entry of NF-κB into the nucleus to regulate synthetic matrix gene transcription. Inhibition of TRPV4 altered primary cilia expression in response to LIPUS stimulation, and knockdown of primary cilia similarly inhibited TRPV4 function. These results suggest that LIPUS mediates TRPV4 channels through primary cilia to regulate the process of knee osteoarthritis in mice.
Constipation is a common symptom in the pediatric clinics. It is usually defined in terms of difficulty of passage of faeces, faecal consistency and frequency of evacuation. A diet containing high amounts in fiber can promote beneficial effects constipation therapy. Beside the fiber, functional foods, such as prebiotics, have been considered useful to regulate bowel movements. Prebiotic is defined as nondigestible food components that affect the host for stimulating selectively growth of potentially beneficial bacteria in the intestines, specially the colon. Nowadays, there are few clinical trials evaluating prebiotic use for relieving constipation symptoms in children. This clinical trial aimed to evaluate the effect of Galactooligossacharides (GOS) on constipated children. The trial consisted of a 75-day period double blind intervention, controlled with placebo and cross over delimitation, with two sequences of evaluation and two treatments, placebo and galactooligossacharides. It included 20 children (4-16 years) with functional constipation defined by the ROMA III criteria. Children have received 6g of GOS or 6g Maltodextrin (placebo), the solution was ingested for 30 days, followed by a washout period of 15 days, and afterwards, 30 more days of GOS or Maltodextrin, alternately with the product ingested in the first 30 days. The study was designed according to crossover delimitation (GOS and Placebo). Eleven patients were evaluated according to the sequence GOS/placebo and nine patients with the sequence Placebo/GOS. A severity score was measured at the beginning, 2nd and 4th week in each experiment. Clinical scores, elaborated for this Trial, were used to evaluate the effect of the products considering: stool frequency, presence of pain/discomfort/effort during evacuation, consistency of stool and loss of appetite or early satiety. Scores were calculated at day zero (D0), 15th day (D15) and 30th day (D30) of the study, in each phase of the "crossover". Oroanal transit evaluation was performed on D0 and D30 of each sequence, by activated charcoal ingestion.

Descriptive analysis trough measures of position and dispersion were realized for numerical variables. ANOVA was used for the analysis of GOS effect. The significance level assumed for the statistical tests was 5%. The GOS presented significant effect compared to placebo, reducing the stool consistency p\< 0,0001 and rising the stool frequency, p=0,0014. The value of the oroanal transit time were significant lower in GOS period, p\<0,0001. GOS was effective at the improvement of mild constipation symptoms and may represent an alternative option for the therapy of this condition.
Inflammation is an initial biological reaction that occurs in response to infection caused by foreign pathogens or injury. This process involves a tightly controlled series of signaling events at the molecular and cellular levels, with the ultimate goal of restoring tissue balance and protecting against invading pathogens. Malfunction in the process of inflammation can result in a diverse array of diseases, such as cardiovascular, neurological, and autoimmune disorders. Therefore, the management of inflammation is of utmost importance in modern medicine. Nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids have long been the mainstays of pharmacological treatment for inflammation, effectively alleviating symptoms in many patients. Recently, toxins and venom, formerly seen as mostly harmful to the human body, have been recognized as possible medicinal substances for treating inflammation. Organisms that are venomous, such as spiders, scorpions, snakes, and certain marine species, have developed a wide range of powerful toxins that can effectively disable or discourage predators. Remarkably, the majority of these poisons and venoms consist of proteins and peptides, which are acknowledged as significant bioactive compounds with medicinal potential. The goal of this review is to investigate the medicinal potential of peptides derived from venoms and their complex mechanism of action in suppressing inflammation. This review also discusses various challenges and future prospects for effective venom delivery.
In this condition, participants will be fitted with 3 different adjustable transfemoral sockets by a certified prosthetist. The order in which the sockets are fitted are randomized and the participant will spend approximately 4 weeks in each socket.
Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (\~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 ...) of each 28 day cycle for up to 24 months.
PCT No. PCT/JP96/00291 Sec. 371 Date Sep. 11, 1997 Sec. 102(e) Date Sep. 11, 1997 PCT Filed Feb. 9, 1996 PCT Pub. No. WO96/26233 PCT Pub. Date Aug. 29, 1996The present invention relates to a polyether polymer having structural units represented by general formula (1), wherein R1 and R2 mean individually an alkyl group of 1-20 carbon atoms, which may have at least one hydroxyl group, and Y denotes an alkylene group of 1-10 carbon atoms, which may have a hydroxyl group, a preparation process thereof, and a moisturizer, a cosmetic composition and a detergent composition comprising this polymer. The cosmetic composition and detergent composition are excellent in moisture retention, keep up the moisturizing effect over a long period of time and give users a pleasant feeling.
539,239. Synthetic resin articles. ORALITE CO., Ltd., and MERRILL, H. W. March 1, 1940, No. 3885. [Class 2 (iii)] [Also in Group VI] Artificial dentures are made by forming a wax model with porcelain teeth, investing it in a mould with dental plaster, removing and filling the mould with synthetic resin of which the entire denture with teeth is made, a single curing only being performed as by boiling for 65 minutes in a closed flask. The teeth cavities may be filled with different artificial resin from that used for the palate and gums, methacrylate and vinyl resins being mentioned.
It is intended to provide an external preparation for skin, which has an effect of improving rough skin, and is excellent in feeling of use, particularly excellent in smoothness, free of stickiness, and excellent in stability. Further, it is intended to provide a cleansing agent for skin which is particularly excellent in usability, and has an excellent effect of removing cosmetics. That is, the external preparation for skin according to the invention is characterized by containing a block type alkylene oxide derivative represented by the following formula (I). Y-[O(EO)a-(AO)b-(EO)c-R]k (I) (In the formula, Y is a residue obtained by removing a hydroxy group from a polyhydric alcohol having 3 to 6 hydroxy groups, k is the number of hydroxy groups of the polyhydric alcohol, EO is an oxyethylene group, AO is an oxyalkylene group having 3 to 6 carbon atoms, and the respective groups are added in the form of a block. a × k, b × k and c × k are average added mole numbers of oxyethylene group, oxyalkylene group having 3 to 6 carbon atoms and oxyethylene group, respectively, and satisfy the following relationships: 0 ≤ a × k ≤ 100, 1 ≤ b × k ≤ 100, 0 ≤ c × k ≤ 100, with the proviso that (a+c) × k > 1. The ratio of the total oxyethylene groups in the formula (I) to the sum of the total oxyethylene groups in the formula (I) and oxyalkylene groups having 3 to 6 carbon atoms is 10 to 80% by mass. The R groups may be the same or different and each is a hydrocarbon group having 1 to 4 carbon atoms.) Further, the cleansing agent for skin according to the invention is characterized by containing 0.01 to 70% by mass of a block type alkylene oxide derivative represented by the above formula (I) and 0.1 to 20% by mass of a moisturizing agent.